JP7097850B2 - 遠視のリスクを判定する方法 - Google Patents
遠視のリスクを判定する方法 Download PDFInfo
- Publication number
- JP7097850B2 JP7097850B2 JP2019081714A JP2019081714A JP7097850B2 JP 7097850 B2 JP7097850 B2 JP 7097850B2 JP 2019081714 A JP2019081714 A JP 2019081714A JP 2019081714 A JP2019081714 A JP 2019081714A JP 7097850 B2 JP7097850 B2 JP 7097850B2
- Authority
- JP
- Japan
- Prior art keywords
- snp
- genotype
- disease
- risk
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010020675 Hypermetropia Diseases 0.000 title description 3
- 230000004305 hyperopia Effects 0.000 title description 3
- 201000006318 hyperopia Diseases 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 33
- 230000002596 correlated effect Effects 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000012549 training Methods 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 88
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 88
- 230000000052 comparative effect Effects 0.000 description 23
- 210000000349 chromosome Anatomy 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000000523 sample Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000007477 logistic regression Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013527 convolutional neural network Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081714A JP7097850B2 (ja) | 2019-04-23 | 2019-04-23 | 遠視のリスクを判定する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081714A JP7097850B2 (ja) | 2019-04-23 | 2019-04-23 | 遠視のリスクを判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020178544A JP2020178544A (ja) | 2020-11-05 |
| JP2020178544A5 JP2020178544A5 (enrdf_load_stackoverflow) | 2022-03-15 |
| JP7097850B2 true JP7097850B2 (ja) | 2022-07-08 |
Family
ID=73022539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081714A Active JP7097850B2 (ja) | 2019-04-23 | 2019-04-23 | 遠視のリスクを判定する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7097850B2 (enrdf_load_stackoverflow) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004173505A (ja) | 2002-11-22 | 2004-06-24 | Mitsuo Itakura | 疾患感受性遺伝子の同定方法並びにそれに用いるプログラムおよびシステム |
| WO2009044294A2 (en) | 2007-06-15 | 2009-04-09 | Université De Geneve | Means and methods for the treatment of cataract and presbyopia |
| JP2012094143A (ja) | 2010-10-27 | 2012-05-17 | Samsung Sds Co Ltd | バイオマーカー抽出装置および方法 |
| WO2018200980A1 (en) | 2017-04-28 | 2018-11-01 | Avellino Lab Usa, Inc. | Methods for detecting alleles associated with keratoconus |
-
2019
- 2019-04-23 JP JP2019081714A patent/JP7097850B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004173505A (ja) | 2002-11-22 | 2004-06-24 | Mitsuo Itakura | 疾患感受性遺伝子の同定方法並びにそれに用いるプログラムおよびシステム |
| WO2009044294A2 (en) | 2007-06-15 | 2009-04-09 | Université De Geneve | Means and methods for the treatment of cataract and presbyopia |
| JP2012094143A (ja) | 2010-10-27 | 2012-05-17 | Samsung Sds Co Ltd | バイオマーカー抽出装置および方法 |
| WO2018200980A1 (en) | 2017-04-28 | 2018-11-01 | Avellino Lab Usa, Inc. | Methods for detecting alleles associated with keratoconus |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020178544A (ja) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7161441B2 (ja) | 慢性副鼻腔炎のリスクを判定する方法 | |
| JP7099983B2 (ja) | 加齢黄斑変性のリスクを判定する方法 | |
| JP7165098B2 (ja) | 動脈硬化のリスクを判定する方法 | |
| JP7165617B2 (ja) | 高血圧のリスクを判定する方法 | |
| JP7097850B2 (ja) | 遠視のリスクを判定する方法 | |
| JP7097849B2 (ja) | 過敏性腸症候群のリスクを判定する方法 | |
| JP2020178555A (ja) | 緑内障のリスクを判定する方法 | |
| JP2020178561A (ja) | 心筋梗塞及び／又は狭心症のリスクを判定する方法 | |
| JP7097854B2 (ja) | 子宮筋腫のリスクを判定する方法 | |
| JP7099980B2 (ja) | 双極性障害のリスクを判定する方法 | |
| JP7096784B2 (ja) | 妊娠糖尿病のリスクを判定する方法 | |
| JP2020178586A (ja) | 接触性皮膚炎のリスクを判定する方法 | |
| JP7097852B2 (ja) | 子宮内膜症のリスクを判定する方法 | |
| JP7097845B2 (ja) | 近視のリスクを判定する方法 | |
| JP7099979B2 (ja) | 脂質異常症のリスクを判定する方法 | |
| JP7160751B2 (ja) | 膠原病のリスクを判定する方法 | |
| JP7099985B2 (ja) | 角膜疾患のリスクを判定する方法 | |
| JP7099982B2 (ja) | 自律神経失調症のリスクを判定する方法 | |
| JP7097851B2 (ja) | 乱視のリスクを判定する方法 | |
| JP7099984B2 (ja) | 白内障のリスクを判定する方法 | |
| JP7097846B2 (ja) | 胃炎のリスクを判定する方法 | |
| JP2020178550A (ja) | 食物アレルギーのリスクを判定する方法 | |
| JP2020174638A (ja) | 慢性中耳炎のリスクを判定する方法 | |
| JP2020178554A (ja) | 化学物質過敏症のリスクを判定する方法 | |
| JP2020174625A (ja) | 過食症のリスクを判定する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220304 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220530 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220628 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7097850 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |